iPS Cell Corneal Regeneration: Japan's Reimei Launches World-First Clinical Trial of Donor-Derived Cell Sheet
Osaka University spinoff Reimei has launched the world's first corporate clinical trial of a corneal epithelial cell sheet made from donor-derived iPS cells, with the first transplant performed on July 9, 2026. How the approach could ease the global corneal donor shortage, what the Lancet-published first-in-human data showed, and where Japan's regenerative medicine regulation stands against the US FDA.